Sponsor Pipeline

Adverum Biotechnologies, Inc. Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
6
Active Trials
2
Recruiting
2
Phase 3
1
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-08-06 NCT07630649
Ixoberogene Soroparvovec (Ixo-vec) Contralateral Dosing Study in Participants With…
Trial sites expanded: 4 -> 12 locations
Active Trials by Phase
Phase 3
2
Phase 2
2
Not specified
2
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT07482176 Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With… Neovascular Age-Related Macular Degeneration (nAMD) Recruiting
NCT06856577 Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With… Neovascular Age-Related Macular Degeneration (nAMD) Active, Not Recruiting
Phase 2
NCT07630649 Ixoberogene Soroparvovec (Ixo-vec) Contralateral Dosing Study in Participants With… Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD Recruiting
NCT05536973 Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular… Neovascular Age-related Macular Degeneration Active, Not Recruiting
Not specified
NCT05607810 Long-Term Follow-up Study of ADVM-022 in DME (INFINITY-EXT) Diabetic Macular Edema Active, Not Recruiting
NCT04645212 Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT] Wet Age-related Macular Degeneration Active, Not Recruiting
Get alerts when Adverum Biotechnologies, Inc.'s trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free